HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low advanced Glycation end product diet improves the central obesity, insulin resistance and inflammatory profiles in Iranian patients with metabolic syndrome: a randomized clinical trial.

Abstract
The study aimed to investigate the effects of 8-weeks AGEs restricted diet on glycemic control as well as lipid profile, inflammatory and oxidative stress biomarkers and IR in overweight patients with Mets. In this randomized, controlled clinical trial 40 clients were randomly assigned to take either a low AGE (L-AGE) or a regular AGE (Reg-AGE) diet. Also, both groups were advised to follow an energy-restricted diet. At baseline and after 8-weeks of intervention, anthropometric parameters, dietary intake, plasma concentrations of malondialdehyde, carboxymethyllysine, TNF-α, hs-CRP and levels of serum glucose, lipid and insulin were assessed. AGEs restriction resulted in significant changes in mean differences levels of CML (p < 0.004), FBG (p < 0.01), HOMA-IR (p < 0.04), TNF-α (p < 0.01) and MDA (p < 0.02) in comparison to Reg-AGE. Moreover, weight (p < 0.0001) and WC (p < 0.001) significantly declined in the intervention group. Our results indicate that dAGEs restriction plus a low-calorie diet is superior to a low-calorie diet in amelioration of central obesity and IR at least partially through reduction of OS and inflammation in Mets subjects.
AuthorsRazieh Goudarzi, Meghdad Sedaghat, Mehdi Hedayati, Azita Hekmatdoost, Golbon Sohrab
JournalJournal of diabetes and metabolic disorders (J Diabetes Metab Disord) Vol. 19 Issue 2 Pg. 1129-1138 (Dec 2020) ISSN: 2251-6581 [Print] Switzerland
PMID33520830 (Publication Type: Journal Article)
Copyright© Springer Nature Switzerland AG 2020.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: